ServiziMenu principaleHome
You are here: Home > What we do > Past events > 2020 > POSTPONED: 8th ESO-SIOP Europe Masterclass in Paediatric Oncology
Share Print

POSTPONED: 8th ESO-SIOP Europe Masterclass in Paediatric Oncology

Not eligible for ESCO credits

28.11.2020  -  03.12.2020

Bucharest, Romania


Paediatric oncology

Important information

On behalf of ESO and SIOP-Europe we would like to inform you that due to the ongoing Coronavirus (COVID-19) crisis we have made the difficult decision to postpone the 8th ESO-SIOP Europe Masterclass in Paediatric Oncology programmed for 28 November - 3 December in Bucharest, Romania.

We deeply regret having to take this decision but we feel that in the current climate we all need to do our part in trying to limit the diffusion of the virus as much as possible and this was the only decision possible considering your role in society as medical staff.

We apologize for any inconvenience caused but we think you’ll all agree that this solution was unavoidable.

The next Masterclass will be held on 27 November - 2 December 2021, in Bucharest, Romania. Further information is available HERE.


Chairs: S. Bielack, DE - B. Morland, UK - C. Stefan, RO/ZA
Host Chair: M. Dragomir, RO

ESO and SIOP-Europe are pleased to announce the eighth Masterclass in Paediatric Oncology. This clinically-oriented educational programme has been designed for young paediatric oncologists, who wish to improve their skills in clinical management of common childhood tumours. It is designed to offer a unique learning experience, providing practice-oriented training and the teaching sessions will focus on the application of the most recent research findings to clinical practice.

• Improve knowledge in the field
• Improve skills in dealing with cancer problems as a whole
• Improve knowledge of current clinical practice and state-of-the-art treatment

• Bone tumours
• Central nervous system tumours
• Leukemia
• Lymphoma
• Neuroblastoma
• Rare tumours
• Soft-tissue sarcoma
• Wilms’ tumour

The Masterclass in Paediatric Oncology is an ESO-SIOP Europe joint event




A. Attarbashi, St. Anna’s Kinderspital, Vienna, AT
P. Berlanga, Gustave Roussy, Paris, FR
S. Bielack, Olgahospital, Dept. of Oncology, Stuttgart, DE
G. Bisogno, Onco-Haematology Clinic, Department of Paediatrics, Padova, IT
A. Colita, Fundeni Clinical Institute, Bucharest, RO
F. Doz, Institut Curie, Paediatric Oncology Dpt., Paris, FR
M. Dragomir, Institutul Oncologic ‘Prof. Dr. Al. Trestioreanu’, Bucharest, RO
A. Eggert, Charité - Berlin University, Department of Paediatric Oncology/ Haematology, Berlin, DE
D. Frappaz, IHOPe and Centre Léon Bérard, Lyon, FR
J. Grill
, Institut Gustave Roussy, Department of Pediatrics, Villejuif, FR
H. Hasle, Aarhus University Hospital, Aarhus, DK
A. Hoy, Consultant in Palliative Medicine, Epsom, UK
D. Körholz, Universitätsklinikum, Halle, Halle, DE
B. Morland, Birmingham Childrens’ Hospital, Birmingham, UK
D. Orbach, Institut Curie, Paediatric Department, Paris, FR
D. Schneider, Klinikum Dortmund, Children’s Department, Dortmund, DE
M. Schrappe, University of Kiel, Department of Paediatrics, Kiel, DE
T. Simon, University Clinic Köln, Pediatric Oncology/Hematology Dpt., Köln, DE
F. Spreafico, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT
C. Stefan, AMRII, ZA

General information

Alexandra Zampetti
European School of Oncology (ESO)
Piazza Indipendenza 2
6500 Bellinzona
ph +41 91 820 09 54
e-mail: azampetti@eso.net

Dolores Knupfer, dknupfer@eso.net, ph: +41 91 820 0952

The 8th ESO - SIOP Europe Masterclass in Paediatric Oncology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.
The programme has been granted up to 34 European CME credits (ECMEC). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Participants will receive their certificate of attendance via e-mail after on completion of the evaluation form.


Being selected to take part in an ESO Masterclass is one of the ESO activities that gives participants eligibility to enrol in ESCO - the College of the European School of Oncology.

A Masterclass also enables ESCO students to earn ESCO credits and therefore access more ESCO benefits. Full and active participation in the Masterclass earns participants 30 ESCO credits.
Visit www.esco.org for information on how to join ESCO.


• Age between 30 and 40 years
• 2-4 years’ experience in paediatric oncology
• Involvement in scientific activities and clinical trials
• Fluency in English

Admittance to the Masterclass is by competitive application. The successful applicants are granted free registration but the cost of half-board accommodation and transfer to the course venue is EUR 450.- for the period 6-11 June 2020 and travel will be covered by the participants.
All participants will be expected to reside at the course venue and their full participation is compulsory throughout the course.
The Masterclass will be taught entirely in English and fluency in English is necessary for admission.

Four full tuition scholarships will be offered to applicants from Low and Middle Income Countries (LMIC) as defined by the World Bank. In order to be considered for a scholarship, please submit a letter of motivation requesting consideration. Please note that scholarship recipients will be responsible for arranging their own travel to Bucharest.



28 November

 20:00   Welcome from the Chairs followed by dinner 

 29 November

8:00   Registration     
 8:30   Multiple choice pre-test 
Session leader: B. Morland, UK
 9:00   Bone sarcomas/case presentations
S. Bielack, DE
 11:00   Coffee break     
 11:15   Bone sarcomas/case presentations
S. Bielack, DE
 12:45   Lunch break                
Session leader: M. Dragomir, RO
 13:45   CNS Tumor biology
14:15   Medulloblastoma
F. Doz, FR
14:45   HGG and LGG
J. Grill, FR
15:30   Ependymoma
D. Frappaz, FR
 16:00   Coffee break
 16:30   Case presentations


 30 November

Session leader: S. Bielack, DE
8:00   Intracranial Germ Cell Tumours 
D. Schneider, DE  
8:30   Germ Cell Tumours   
D. Schneider, DE
9:30   Hepatoblastoma    
B. Morland, UK
10:30   Very rare tumors
D. Schneider, DE
11:00   Coffee break    
11:30   Case presentations
12:30   Lunch break
 13:30   Key note lecture: T-cells  
Session leader: A. Colita, RO
14:30   ALL
M. Schrappe, DE
 15:30   Management of AML
H. Hasle, DK
16:30   Case presentations
20:00   Offsite dinner, Caru' cu Bere


 1 December

8:00   Communication workshop (RED GROUP)    
 9:00   Key note lecture: Early phase studies (BLUE GROUP)   
B. Morland, UK
 10:00   Coffee break
Session leader: C. Stefan, ZA
10:30   Rhabdomyosarcoma    
G. Bisogno, IT
11:30   Non Rhabdo Soft Tissue Sarcoma   
12:30   Questions and discussion   
13:00   Lunch break   
14:00   Case presentations
16:00   Coffee break 
16:30   Communication workshop (BLUE GROUP)   
16:30   Key note lecture: Early phase studies (RED GROUP)
B. Morland, UK  
    Free evening     


 2 December

Session leader: C. Stefan, ZA
8:00   Overview: Non-Hodgkin's Lymphoma
A. Attarbaschi, AT
9:00   Overview: Hodgkin's Lymphoma
10:00   Coffee break 
10:30   Case presentations    
12:30   Lunch
13:30   Keynote lecture: How to identify patients who may benefit from personalised medicine
P. Berlanga, FR   
Session leader: B. Morland, UK
15:00   Current approaches in low risk and intermediate risk neuroblastoma   
T. Simon, DE
16:00   Coffee break      
16:30   Current approaches in high-risk and relapse neuroblastoma
A. Eggert, DE  
19:30   Dinner  


 3 December

Session leader: S. Bielack, DE        
8:00   Overview of renal tumours of childhood and approaches to treatment of Wilms tumour (part I)
F. Spreafico, IT 
8:45   Case presentations   
9:30   Overview of renal tumours of childhood and approaches to treatment of Wilms tumour (part II)
F. Spreafico, IT 
10:15   Case presentations       
 11:30   Multiple choice post-test 
 12:00   Discussion and closure
12:30   Standing brunch
13:00   Group transfer from hotel to airport